The country of Georgia has a high burden of multi-and extensively drug-resistant tuberculosis (XDR-TB). To evaluate whether mutations in gyrB and eis genes increased the sensitivity of detection of phenotypic resistance to ofloxacin and kanamycin or capreomycin compared to use of the first-generation MTBDRsl assay alone, which tests for mutations in gyrA and rrs genes, a retrospective study of stored Mycobacterium tuberculosis isolates was performed. All isolates underwent DNA sequencing of resistance-determining regions. Among 112 M. tuberculosis isolates with DNA extraction data, targeted sequencing was successfully performed for each gene as follows: for gyrA, 98% sensitivity; for gyrB, 96%; for rrs, 93%; for the eis gene and its promoter, 93%. The specificity and hence the positive predictive value of gyrA and gyrB mutations for detecting ofloxacin resistance were 100%. The addition of gyrB mutations increased the sensitivity of phenotypic ofloxacin resistance detection by 13% (75% to 88%). All rrs resistance-conferring mutations were A1401G, and this mutation had low sensitivity (40% and 18%) and high specificity (95% and 100%) in predicting phenotypic capreomycin and kanamycin resistance, respectively. The eis C-14T mutation increased the sensitivity of phenotypic kanamycin resistance detection by 9% (18% to 27%) and was found solely in kanamycin phenotypic resistance isolates. Our data showed that the inclusion of eis C-14T and gyrB mutations in addition to rrs and gyrA mutations improves the sensitivity of detection of phenotypic ofloxacin and kanamycin resistance, respectively.
T he year of 2016 marked a critical juncture in the battle against tuberculosis (TB) as new goals outlined in the Sustainable Developmental Goals (SDGs) and the End TB Strategy called for accelerated action to reduce the incidence of the disease by at least 90% over the next 2 decades (1, 2) . A major threat to these goals is the continued emergence of multidrug-resistant (MDR) and, even more concerning, extensively drugresistant (XDR) TB (3) . The 2016 World Health Organization (WHO) report noted a continued high global incidence of MDR TB at 580,000 new cases and further resistance in the form of XDR strains at a rate of approximately 10% among those with MDR. XDR TB has now been documented in 105 countries (1) . Outcomes for patients with MDR and XDR TB remain poor due in part to difficulties in detection of drug resistance and lack of optimal antituberculosis medications (4) .
An area that offers great promise in improving drug-resistant-TB management is the introduction of rapid molecular diagnostic tests. Modeling work suggests that the implementation of rapid diagnostics and subsequent initiation of effective treatment can have a major effect on reducing the burden of drug-resistant TB (5, 6) . The endorsement and rollout of a line-probe assay (LPA) (Genotype MTBDRplus; HainLifescience) and the Xpert MTB/RIF (Cepheid) assay have been a testament to the benefits of rapid testing (1) . The Xpert assay and LPA have both been shown to drastically reduce the time to detection of MDR TB, in most cases by over a month compared to culture and drug susceptibility testing (DST) (7, 8) . Additionally, we previously demonstrated that implementation of the MTBDRplus assay led to a significantly reduced time to culture conversion and implementation of proper infection control measures among patients with MDR TB in the country of Georgia (9) . An accurate rapid molecular test for detection of fluoroquinolones and injectable agents (kanamycin, amikacin, and capreomycin) is needed to realize similar benefits for patients with XDR TB.
The MTBDRslV1 assay detects mutations in the gyrA gene (coding for subunit A of DNA gyrase) and the rrs gene (coding for16S rRNA) as a means to determine phenotypic fluoroquinolone and injectable-drug resistance, respectively. A recent review on the performance of the MTBDRslV1 assay concluded that the test is able to accurately rule in drug resistance but is precluded from ruling out resistance due to low sensitivity, especially for kanamycin resistance (10) . We reported a similar lack of sensitivity in detected XDR-TB in using the MTBDRslV1 LPA in Georgia. We found suboptimal performance for detection of phenotypic drug resistance to ofloxacin (81% sensitivity), capreomycin (57%), kanamycin (27%), and XDR TB (41%) compared to that of traditional phenotypic DST (11) .
More-recent work has found that the inclusion of tests for additional mutations in the gyrB and eis genes may improve the detection of phenotypic resistance to tofluoroquinolones and kanamycin, respectively (12) (13) (14) (15) , and those results have also led to the development of the MTBDRslV2 assay, which includes tests for gyrB and eis promoter mutations (16) . We sought to evaluate whether we could improve the molecular detection of phenotypic ofloxacin, kanamycin, and capreomycin resistance using the MTBDRslV1 assay through the inclusion of tests for additional mutations in gyrB and eis promoter genes, including those found in the newer MTBDRslV2 assay, utilizing targeted DNA sequencing. Georgia continues to be inflicted with high rates of XDR TB, and the results of this study are expected to help efforts to develop an accurate rapid test for XDR TB that will work in our setting and in other, similar settings. An accurate rapid test for XDR TB would help pave the way for timely introduction of effective treatment.
RESULTS
Among the 112 Mycobacterium tuberculosis isolates with DNA extraction, targeted sequencing was successfully performed for each gene as follows: for gyrA, 98% (110/ 112) sensitivity; for gyrB, 96% (107/112); for rrs, 93% (104/112); for the eis gene and its promoter, 93% (104/112). The primer sequences for amplification of the four gene targets in the gyrA, gyrB, and rrs genes and in the eis gene and its promoter are listed in Table 1 .
Sixteen (14%) of the 112 M. tuberculosis isolates were phenotypically resistant to ofloxacin. No gyrA or gyrB mutations were identified by either MTBDRslV1 testing or targeted DNA sequencing in the phenotypically susceptible isolates ( Table 2 ). Among the 16 ofloxacin-resistant isolates, 14 (88%) had a mutation in either gyrA (n ϭ 11) or gyrB (n ϭ 5) according to both tests, and in one case there was the lack of binding to the gyrA wild-type 2 (ΔWT2) probe by the MTBDRslV1 test. Two isolates had both a gyrA and gyrB mutation, and another two isolates had no mutations identified ( Table 2 ). The addition of any gyrB mutation increased the sensitivity of ofloxacin resistance detection from 75% to 88%. The specificity and hence the positive predictive value (PPV) determined for gyrA and for detection of ofloxacin resistance were 100% (Table 3) . gyrA mutations D94G (n ϭ 6) and A90V (n ϭ 5) were the most common mutations ( Table 2) . One isolate had a gyrA mutation identified by the MTBDRsl assay but not by sequencing, while another isolate had a gyrA mutation found by sequencing but not by the MTBDRsl assay. The overall agreement between molecular detection of gyrA and a combination of gyrA and gyrB mutations for phenotypic ofloxacin resistance was high (kappa values of 0.84 and 0.92, respectively) ( Table 3) .
Among the 112 M. tuberculosis isolates, 15 (13%) and 63 (56%) were phenotypically resistant to capreomycin and kanamycin, respectively (Tables 4 and 5). With the exception of one susceptible isolate with an rrs mutation (C1443G), the only rrs mutation detected by the MTBDRsl assay and targeted sequencing was A1401G (Tables 4 and 5). In regard to capreomycin, the rrs A1401G mutation was found in 6 of 15 (40%) and 4 of 97 (4%) phenotypically resistant and susceptible isolates, respectively ( Table 4 ). Any eis promoter mutations were found in isolates phenotypically susceptible (25/97, 26%) and resistant (4/15, 27%) to capreomycin with similar prevalences. The presence of an rrs mutation had low sensitivity (6 of 15, 40%) and high specificity (90 of 95, 95%) in predicting phenotypic capreomycin resistance ( Table 6 ). There were 2 isolates with 
Ofloxacin phenotypic DST result and no. of isolates

MTBDRsl assay result and mutation(s) b
Gene sequencing result gyrA gyrB Susceptible (n ϭ 96) Susceptible 92
WT
a DST, drug susceptibility testing; Δ, indicated lack of wild-type band; WT, wild type; MT, mutation; NA, not available. b gyrA gene region or mutation analyzed: WT2, positions 89 to 93; W3, positions 92 to 97; MT1, mutation A90V; MT3C, mutation D94G. c Data represent M. tuberculosis isolates with a mutation in both gyrA and gyrB. an rrs mutation found by MTBDRsl testing but not by sequencing, and there was 1 isolate with an rrs mutation found by sequencing but not by MTBDRsl testing.
Of the 63 M. tuberculosis isolates with phenotypic resistance to kanamycin, only 11 were detected either by the presence of an rrs mutation (10) or, in one case of detection by the MTBDRsl assay, by a lack of binding to rrs wild-type probe 1 (ΔWT1). There were 3 isolates with an rrs mutation found by the MTBDRsl assay but not by sequencing, and there was 1 isolate with an rrs mutation found by sequencing but not by the MTBDRsl assay. The rrs A1401G mutation was not found in any isolates phenotypically suscep- WT
a DST, drug susceptibility testing; Δ, indicated lack of wild-type band; WT, wild type; NA, not available. b rrs gene region or mutation analyzed: WT1, positions 1401 to 1402; MT1, mutation A1401G. c C159A is a silent mutation.
tible to kanamycin by either the MTBDRsl assay or targeted sequencing. One isolate had a C1443G mutation detected by targeted sequencing which is not associated with kanamycin resistance. Any eis mutation identified was found on targeted sequencing in 33% (21/63) of the isolates with phenotypic resistance compared to 14% (7/49) of those that were phenotypically susceptible (P Ͻ 0.05). The C-14T mutation was the only eis mutation found solely in kanamycin isolates showing phenotypic resistance. While the presence of an rrs mutation or any eis mutation had the highest sensitivity (49%) for detecting kanamycin resistance, the specificity was 84%. In contrast, detection of the WT
a DST, drug susceptibility testing; Δ, indicated lack of wild-type band; WT, wild type; NA, not available. b rrs gene region or mutation analyzed: WT1, positions 1401 to 1402; MT1, mutation A1401G. c C159A is a silent mutation. presence of an rrs or eis C-14T mutation had lower sensitivity (27%) but retained a high specificity of 100% (Table 6 ). There were 5 isolates, including isolates from both phenotypically resistant and phenotypically susceptible strains, which showed the presence of a silent C159A mutation.
DISCUSSION
Through the molecular characterization of M. tuberculosis isolates from the country of Georgia, we found that detection of mutations in gyrB and eis genes improved the detection of second-line drug resistance. The inclusion of any mutation in gyrB (in addition to mutations in gyrA) and the eis C-14T mutation (in addition to mutations in rrs) increased the sensitivity of detection of phenotypic resistance to ofloxacin and kanamycin by 13% and 9%, respectively. Despite these encouraging findings, however, there was a high rate of M. tuberculosis isolates found to be phenotypically resistant to capreomycin and kanamycin without any mutation(s) found in either the rrs gene or the eis gene. While the inclusion of gyrB mutations may increase detection of fluoroquinolone resistance, a better understanding of injectable-drug resistance is still needed to help aid efforts aimed at developing an accurate rapid molecular test.
Among our M. tuberculosis isolates, the inclusion of any gyrB mutation increased the sensitivity of detection of phenotypic ofloxacin resistance from 75% to 88% and slightly increased the negative predictive value (NPV) for ofloxacin resistance from 96% to 98%. This high NPV would be useful for clinicians in regard to ruling out ofloxacin resistance and in developing an individualized drug resistance treatment regimen. The value of inclusion of gyrB mutations to increase the rate of detection of phenotypic fluoroquinolone has been show to vary in different settings. A study from France found results similar to ours in that the inclusion of gyrB mutations increased detection of phenotypic fluoroquinolone resistance by 12% (14), while a large multicenter study performed with M. tuberculosis isolates from India, Moldova, Philippines, and South Africa found no benefit of inclusion of gyrB mutations (17) . Additionally, in a large sequencing study of 1,397 geographically diverse M. tuberculosis isolates, the only gyrB mutation which was found to have predictive value in analyses of ofloxacin phenotypic resistance was N538T, which was found in only one of our five isolates with a gyrB mutation (18) .
Among five isolates with gyrB mutations and phenotypic ofloxacin resistance, three had additional gyrA mutations and two had only a gyrB mutation, including R485H and A543V. Results from a functional genetic study suggested that the A543V mutation in isolation was not sufficient to cause fluoroquinolone resistance; however, the mutated Erdman strain used in the study had an elevated ofloxacin MIC of 2 g/ml, and the A543V mutation was found also in two fluoroquinolone-resistant but no fluoroquinolonesusceptible isolates from another study in France (14, 18) . Limited data have also not shown an association with R485H phenotypic fluoroquinolone resistance and that phenotypic fluoroquinolone resistance may not be due to a single mutation but may in some cases be due to the interaction of gyrA and gyrB mutations (19) . Thus, in our two cases of phenotypic ofloxacin resistance with only a gyrB mutation (R485H, A543V), it is unclear if the resistance was due to these mutations or to an additional, unknown mechanism. If the newer MTBDRslV2 assay were to have been used to detect fluoroquinolone and injectable agent resistance, our two cases of phenotypic ofloxacin resistance with only gyrB mutations would not have been detected, as it detects gyrB mutations only at codons 536 to 541 (16) . Further building of globally diverse M. tuberculosis mutation and phenotypic resistance databases such as that by Farhat et al. (19) is necessary to determine the utility of mutations in predicting resistance and which mutations to include in rapid molecular tests.
Although we found rrs mutations detected by the MTBDRslV1 assay and/or targeted sequencing to be the most common genetic mutations associated with injectable-drug resistance, their sensitivities for detection of capreomycin resistance (40%) and kanamycin resistance (18%) were extremely low. This low sensitivity has been well documented, especially in Eastern Europe and Russia (10, 12) . The addition of any eis mutation increased the sensitivity of kanamycin resistance detection from 18% to 49%; however, the sacrifice was a decrease in specificity from 100% to 84%. In contrast, the inclusion of only the eis C-14T mutation still increased the sensitivity of detection of kanamycin resistance from 18% to 27%, although the increase was less than that seen with the eis mutations, but maintained the high specificity of 100%. Mutations in the eis promoter region were shown to cause aminoglycoside resistance by increasing the amount of aminoglycoside acetyltransferase, thereby leading to drug inactivation (13) . There is a preferential effect for resistance to kanamycin over amikacin due to a much higher acetylation rate for kanamycin, and the eis C-14T mutation was associated with the highest kanamycin MIC values compared to G-10A and C-12T mutations. eis mutations are not associated with capreomycin resistance; thus, our finding of similar rates of eis mutations in capreomycin-resistant and -susceptible isolates was not unexpected.
Studies of clinical M. tuberculosis isolates have found that the eis C-14T mutation is very specific for kanamycin resistance whereas the eis C-12T and G-10C mutations are not very specific, being found in many kanamycin-susceptible isolates (12, 15, 16, 20, 21) . The eisG-10A mutation has been found to be associated with lower phenotypic resistance in vitro (13) than the C-14T mutation, and while most studies show 100% specificity of the G-10A mutation for phenotypic kanamycin resistance (12, 15) , there are a few M. tuberculosis isolates, including two from our study, reported to have the G-10A mutation and susceptibility to kanamycin (20) . The emerging data on the differential effects of eis mutations on phenotypic aminoglycoside resistance will be important in guiding clinicians with respect to interpreting the results obtained with the new MTBDRslV2 test, which, in addition to detecting rrs mutations, detects mutations in the eis promoter region Ϫ10 to Ϫ14 (16) .
Limitations of our study also included the lack of tlyA sequencing and MIC testing. A prior study from Georgia found no tlyA mutations among 60 M. tuberculosis isolates with phenotypic resistance to capreomycin; thus, tlyA mutations were unlikely to account for our results showing a high proportion of unexplained capreomycin resistance (22) . MIC testing would have allowed us to determine if the isolates with an A1401G mutation and capreomycin susceptibility harbored low-level resistance, as has been previously suggested (23) . The inclusion of levofloxacin and moxifloxacin DST and MIC testing would have provided important data with respect to clinically utilized fluoroquinolones and the association of certain mutations with low-or high-level resistance as well as fluoroquinolone cross-resistance (24) . Additionally, the critical concentration of ofloxacin (2.0 g/ml) on LJ medium utilized for susceptibility testing was the previously recommended concentration and in 2012 was increased to 4.0 g/ml. Thus, we may have overestimated ofloxacin phenotypic resistance, particularly in regard to the two M. tuberculosis isolates with phenotypic ofloxacin resistance and no mutations identified. The small number of M. tuberculosis isolates with phenotypic resistance to ofloxacin and capreomycin was also a limitation that led to large confidence intervals for sensitivity calculations. Additionally, as possible reasons for the low sensitivity of genetic mutations for detecting phenotypic capreomycin and kanamycin resistance, we could not rule out errors in DST which may have led to misclassification of M. tuberculosis isolates as falsely resistant or the potential effect of the presence of heteroresistant bacterial populations. Such heteroresistant bacterial populations may have been the cause of the discordance between the MTBDRslV1 assay results and the genetic sequencing results and also of the low sensitivity of genetic mutations in predicting phenotypic resistance, as DST has been shown to be able to detect a lower percentage of resistant bacterial subpopulations (down to 1%) than molecular methods (25, 26) . Lastly, we were unable to successfully sequence all our M. tuberculosis isolates, a result which may be have been due to the presence of damaged DNA or to deletions or mutations at primer binding sites.
Conclusion. As shown by the results of the study, the inclusion of certain gyrB mutations and eis mutations may increase the sensitivity of detection of ofloxacin and kanamycin resistance, respectively. Continued efforts at building a globally diverse database of M. tuberculosis isolates with detailed genetic and phenotypic DST data will help clarify which mutations and/or combinations of mutations confer phenotypic drug resistance and which can be feasibly included in a rapid molecular test. The recently released consensus statement from the TBNET and RESIST-TB groups on the clinical implications of molecular drug resistance testing is a great starting point, and we are hopeful that our results, along with those from other studies, will provide the data needed to provide guidance also on gyrB and eis mutations in the near future (27) . Additionally, further evaluation on the cause of unexplained kanamycin and capreomycin resistance is needed. Study samples, culture, and DST. The M. tuberculosis isolates used for this study were obtained from a frozen collection and were mostly from patients who had been enrolled in a previous study evaluating the performance of the MTBDRsl assay (11) . The study population consisted of consecutive patients with documented MDR TB from throughout the country of Georgia during the period of November 2011 to April 2012. A total of 112 M. tuberculosis isolates from the 143 culture-positive patients with complete MTBDRslV1 results in our prior study were available and able to be subcultured at the NRL per standard methodology (7) . After frozen isolates were thawed at room temperature, a 0.5-ml suspension was inoculated onto two Lowenstein-Jensen (LJ) slants, which were incubated at 37°C until confluent growth was observed. DST of second-line drugs was previously done on all the isolates using the proportion method and LJ medium with the following drug concentrations: for ofloxacin, 2.0 g/ml; for para-aminosalicylic acid, 0.5 g/ml; for capreomycin, 40.0 g/ml; for kanamycin, 30.0 g/ml (11) .
MATERIALS AND METHODS
Setting
DNA extraction and sequencing. DNA extraction was performed using a QIAamp DNA minikit (Qiagen Inc., Valencia, CA). DNA extracts were shipped from the NCTLD to the PHRI, where targeted genetic sequencing was performed. Genomic DNA was subjected to PCR (the primers used for the gyrA, gyrB, and rrs genes and for the eis gene and its promoter are listed in Table 1 ) followed by Sanger sequencing of coding DNA sequences. The positions corresponding to the beginning and end for each amplicon were based on the map of the M. tuberculosis H37Rv reference strain using Tuberculist (http://genolist.pasteur.fr/TubercuList/) and are as follows: for gyrA, positions 7340 to 7699; for gyrB, 6968 to 7064; for rrs, 1472694 to 1473446; for the eis gene, 2714035 to 2714823; for the eis promoter, 2714594 to 2715411. Mutations were identified by alignment of nucleotide sequences to those of the M. tuberculosis H37Rv reference strain (NCBI accession number AL123456) (28) using ClustalW2 as previously described (17) . The MTBDRslV1 results from our prior study were available, and the test was performed as previously described (11) .
Data analysis. All data analyses were carried out using SAS, version 9.4 (Statistical Analysis Software Institute, Cary, NC, USA). The sensitivity, specificity, positive predictive value, and negative predictive value corresponding to mutations in certain genes in detecting phenotypic resistance to ofloxacin (gyrA, gyrB), capreomycin (rrs, eis promoter), and kanamycin (rrs, eis promoter) were calculated using conventional DST results as the reference standard. For these calculations, if a mutation in the gyrA or rrs gene was found either by the MTBDRsl V1assay or by genetic sequencing, it was considered present. No mutations were found in the eis gene; thus, only eis promoter mutations were included in the data analysis.
Accession number(s). Data have been deposited in GenBank under accession no. MF098543.
